会计年度:2016-12-31收入分布
|
项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
调拨 | 7,438,153,794.50 | 7,218,308,653.48 | 219,845,141.02 | 2.96 |
国际贸易 | 6,842,934,166.30 | 6,097,452,818.33 | 745,481,347.97 | 10.89 |
化学制剂 | 1,412,088,539.29 | 552,889,498.89 | 859,199,040.40 | 60.85 |
其中:纯销 | 9,695,853,604.45 | 8,742,987,079.70 | 952,866,524.75 | 9.83 |
其中:原料药 | 1,078,628,063.26 | 881,675,981.35 | 196,952,081.91 | 18.26 |
医药工业 | 2,491,179,774.39 | 1,434,887,686.34 | 1,056,292,088.05 | 42.40 |
医药商业 | 17,134,007,398.95 | 15,961,295,733.18 | 1,172,711,665.77 | 6.84 |
中成药 | 463,171.84 | 322,206.10 | 140,965.74 | 30.43 |
|
会计年度:2016-06-30
|
项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
调拨 | 3,616,834,664.17 | 3,475,381,067.68 | 141,453,596.49 | 3.91 |
国际贸易 | 3,358,492,141.37 | 2,966,775,903.16 | 391,716,238.21 | 11.66 |
合计 | 11,978,956,829.46 | 10,491,005,751.28 | 1,487,951,078.18 | 12.42 |
化学制剂 | 673,791,793.68 | 290,534,047.99 | 383,257,745.69 | 56.88 |
内部抵消 | -405,022,867.25 | -404,567,766.48 | -455,100.77 | -- |
其中:纯销 | 4,187,931,881.21 | 3,742,888,144.89 | 445,043,736.32 | 10.63 |
其中:原料药 | 546,850,741.88 | 419,921,794.04 | 126,928,947.84 | 23.21 |
医药工业 | 1,220,721,009.96 | 710,528,402.03 | 510,192,607.93 | 41.79 |
医药商业 | 7,804,766,545.38 | 7,218,269,212.57 | 586,497,332.81 | 7.51 |
中成药 | 78,474.40 | 72,560.00 | 5,914.40 | 7.54 |
|
会计年度:2015-12-31
|
项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
调拨 | 2,269,492,312.08 | 2,206,852,355.72 | 62,639,956.36 | 2.76 |
国际贸易 | 6,785,007,862.90 | 6,045,952,105.90 | 739,055,757.00 | 10.89 |
合计 | 20,467,359,408.70 | 17,990,633,755.09 | 2,476,725,653.61 | 12.10 |
化学制剂 | 1,152,221,826.85 | 442,305,193.87 | 709,916,632.98 | 61.61 |
内部抵消 | -683,565,488.63 | -682,814,622.44 | -750,866.19 | -- |
其中:纯销 | 9,808,559,218.86 | 9,089,382,812.11 | 719,176,406.75 | 7.33 |
医药工业 | 2,287,865,503.49 | 1,331,261,103.80 | 956,604,399.69 | 41.81 |
医药商业 | 12,078,051,530.94 | 11,296,235,167.83 | 781,816,363.11 | 6.47 |
原料药 | 1,106,480,637.25 | 869,654,814.29 | 236,825,822.96 | 21.40 |
中成药 | 29,163,039.39 | 19,301,095.64 | 9,861,943.75 | 33.82 |
|
会计年度:2015-06-30
|
项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
国际贸易 | 3,268,225,844.03 | 2,817,307,100.49 | 450,918,743.54 | 13.80 |
内部抵消 | -381,673,166.82 | -379,430,526.52 | -2,242,640.30 | -- |
医药工业-化学制剂 | 575,148,122.72 | 235,766,357.39 | 339,381,765.33 | 59.01 |
医药工业-原料药 | 515,284,549.26 | 436,292,328.25 | 78,992,221.01 | 15.33 |
医药工业-中成药 | 14,470,386.02 | 9,559,062.25 | 4,911,323.77 | 33.94 |
医药商业-纯销 | 3,539,458,483.98 | 3,183,706,686.28 | 355,751,797.70 | 10.05 |
医药商业-调拨 | 1,942,050,240.12 | 1,902,904,174.24 | 39,146,065.88 | 2.02 |
|
会计年度:2014-12-31
|
项目名称 | 主营业务收入 | 主营业务成本 | 主营业务毛利 | 毛利率 |
调拨 | 1,756,920,792.57 | 1,708,079,686.59 | 48,841,105.98 | 2.78 |
国际贸易 | 6,266,962,418.01 | 5,634,276,984.85 | 632,685,433.16 | 10.10 |
化学制剂 | 997,105,241.56 | 446,947,266.25 | 550,157,975.31 | 55.18 |
内部抵消 | -341,032,793.75 | -346,915,597.25 | 5,882,803.50 | -- |
其中:纯销 | 7,944,410,445.36 | 7,364,765,929.57 | 579,644,515.79 | 7.30 |
其中:原料药 | 1,130,092,106.26 | 934,582,824.61 | 195,509,281.65 | 17.30 |
医药工业 | 2,155,544,117.46 | 1,399,922,969.86 | 755,621,147.60 | 35.05 |
医药商业 | 9,701,331,237.93 | 9,072,845,616.16 | 628,485,621.77 | 6.48 |
中成药 | 28,346,769.64 | 18,392,879.00 | 9,953,890.64 | 35.11 |
|